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Tuberculosis is a major public health problem in developing countries. It is one of the most widely spread human 
diseases globally. While the new diagnostics for tuberculosis (TB) have created greater interest, their full impact on global 
propaganda against tuberculosis is yet to be evaluated. Most of the TB cases are prevalent in the underdeveloped and 
developing regions of the world where the means to diagnose and to treat TB cases are limited. As a result, the infectious TB 
cases might remain undiagnosed or diagnosed late. So, the need of the hour is to launch a rapid but simple, inexpensive, 
sensitive and specific test to diagnose TB cases at the earliest. The abundant presence of glutamine synthetase (GS) in the 
culture filtrate of pathogenic mycobacteria has correlation with the occurrence of poly L-glutamate/glutamine component in 
the cell wall of these pathogenic mycobacteria but not in non-pathogenic mycobacteria. The GS seems to be stable in the 
infected host and also is present in host tissues and fluid. GS is demonstrated to be present in the serum of subjects suffering 
from pulmonary or extra-pulmonary tuberculosis; but not detectable at all in normal control and disease control (lung 
disease control) subjects. With anti-tubercular (A-TB) drug therapy in pulmonary and extra-pulmonary tubercular subjects, 
the serum GS levels fall significantly. To confirm that only the Mycobacterium tuberculosis (M. tuberculosis) GS is being 
assayed, the serum GS activity may be assayed in the presence of L-methionine-S, R-sulfoximine (MSO), a selective 
inhibitor of M. tuberculosis GS. The concentration of this inhibitor is so selected that it is sufficient to inhibit mycobacterial 
GS activity but not the human (mammalian) GS activity. It increases the specificity of the test. Thus, an ELISA or latex 
agglutination test might be inducted to assay the serum GS activity for the rapid and reliable detection of active or latent 
tubercular subjects and also detecting the presence of drug sensitivity or the emergence of resistance against A-TB drugs. 
Nevertheless, for rapid field study, the card assay technique might be implemented; where when a drop of serum from a 
suspected subject be placed on the substrate for GS; a definite colour change would mark the test positive. 
The assay for serum GS requires only a sample of serum from the patient and takes only few minutes to perform. 
Therefore, the results will be available instantaneously when the patient is at the medical facility centre or even at home and 
this will curtail the number of visits to the medical facility centre. This is really advantageous in developing and 
underdeveloped countries where in many cases the patients do not have the capability of making multiple visits to the 
medical facility centre. The test procedure can also be used as an assay to monitor the response and success of anti-
tubercular drug therapy. The procedure can very well indicate whether the treatment is successful or a change in the 
antibiotic drug therapy would be needed. 
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Worldwide, tuberculosis is one of the 10 causes of 
death and the leading cause from a single infectious 
agent (above HIV/AIDS). In 2017, TB caused an 
estimated 1.3 million deaths among HIV-negative 
people. India bears the major burden (27%) of 
tubercular cases globally
1
. 
The traditional diagnostics for TB as well as the 
newer diagnostics have their limitations and 
drawbacks as mentioned below. 
a) Chest X-ray-insensitive and non specific test. 
b) Sputum microscopy- time consuming and 
having low sensitivity in HIV co-infected 
subjects. 
c) Solid media culture- requires significant lab 
infrastructure and time upto 8 weeks. 
d) Interferon gamma release assays-poor 
performance for active disease. 
e) Fluorescence microscopy-requires specialized 
equipment 
f) Liquid media culture-false positivity can occur 
due to cross-contamination in the lab. 
—————— 
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g) Polymerase chain reaction- Shows a large 
degree of heterogeneity. 
h) X pert MTB- has lower sensitivity in  
HIV-infected patients and is not recommended 
for treatment monitoring. 
i) Line probe assay- expensive and the main use 
being for the rapid detection of drug resistant 
tuberculosis. 
Though greater interest has been produced by the 
newer diagnostics for TB, their full impact on global 
propaganda against TB is yet to be evaluated
2
. 
Instead of the institution of the X pert MTB assay as 
a newer rapid tuberculosis diagnostic, the difference 
between approximate global estimate of incidence and 
new cases of notification is about 4.1 million persons. 
So, to improve the rate of case detection, biomarkers 
are urgently needed, which are rapid, highly specific 
and sensitive to diagnose pulmonary as well as  
extra-pulmonary tubercular subjects and also to indicate 
progression from latent infection to clinical disease, to 
indicate risk of reactivation after cure and also to provide 
accurate end points for drug and vaccine trials
3
. 
The enzyme glutamine synthetase (GS), a 
dodecamer of identical 53 kda, plays a major role in 
nitrogen metabolism by catalyzing the synthesis of  
L-glutamine from L-glutamate, ammonia and ATP. In  
M. tuberculosis, GlnA1 is an essential enzyme as 
glnA1 mutants are not viable in vitro or in vivo and the 
other glnA1 homologs in M. tuberculosis (glnA2-4) 
cannot replace the functional loss of glnA1
4,5
. The 
presence of glutamine synthetase in appreciable 
amount in the culture filtrate of pathogenic 
mycobacteria has been reported. The presence of a poly 
L-glutamate/glutamine component in the cell wall of 
pathogenic mycobacteria (but not in non-pathogenic 
mycobacteria) has a strong correlation with this fact
6,7
. 
The compound L-methionine-SR-sulfoximine 
(MSO) has inhibitory effect on the GS enzyme activity 
of mycobacterial origin including M. tuberculosis but it 
has very little effect on mammalian glutamine 
synthetase
8
. It is also reported that the stability of  
M. tuberculosis GS is fairly high in the culture 
medium
9
.This higher stability might be largely 
responsible for their higher concentration in the 
extracellular medium of broth culture. This fact gives the 
strong indication that this enzyme (GS) has the strong 
possibility to be stable and persistent in the infected host 
tissues and fluids. 
It was reported that treatment of TB subject with 
MSO inhibiting the formation of poly-L-glutamate/ 
glutamine cell wall structure, had shown to inhibit 
mycobacterial growth giving clear indication that the 
GS had played a great role in mycobacterial 
homeostasis
10
. 
 
The complete reaction catalysed by glutamine 
synthetase consists of actually three steps-the transfer 
of phosphate from ATP to glutamate, addition of 
ammonia to phosphorylated glutamate producing 
protonated glutamine and the removal of proton from 
glutamine by the leaving phosphate. This exothermic 
reaction (yielding an activation free energy of  
21.5 kcal/M) might be an opening door for more 
pronounced studies for the development of new  
anti-tuberculosis therapies
11
. Thus, the presence of GS 
was expected as a biomarker in the serum of 
tubercular subjects specially before the institution of 
anti tubercular drugs and its level could have been 
used as a means for monitoring the success of 
treatment. By incorporating MSO, the selective 
inhibitor of pathogenic mycobacteria, as a control in 
serum GS assay; should allow enhanced specificity.  
 
Materials 
The study was conducted at B.S. Medical College 
& Hospital, Bankura-722102(WB), India. The study 
on blood samples obtained from human subjects was 
approved in writing by the Ethics Committee of  
B.S. Medical College & Hospital. Before collection of 
blood, the verbal consent was taken from the 
tubercular subjects as well as from the normal control 
and lung disease control subjects. The following 
groups of subjects were taken into consideration. 
 
Normal control subjects 
They were the healthy relatives of the patient with 
TB but without any clinical signs, symptoms, or  
X-ray findings suggestive of tuberculosis or any sort 
of diseases. Needless to say, they were sputum 
negative for acid fast bacilli. 
 
Disease control subjects (lung disease control) 
They were the patients suffering from respiratory 
tract infection (RTI) or bronchiectasis or bronchial 
asthma or bronchogenic carcinoma. In these subjects, 
there was no sign or symptom at all of tuberculosis. 
They were selected from the patients attending the 
Out Patient Department of B.S. Medical College & 
Hospital, Bankura (WB). 
 
Tubercular subjects 
They were divided into two groups. (A) pulmonary 
and (B) extra pulmonary. The tubercular (TB) 
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subjects (irrespective of age, sex and socio-economic 
status) attending the Out Patient Department of  
B.S. Medical College And Hospital, Bankura (W.B), 
India; and also TB subjects admitted in the Isolation 
Ward of the same hospital were taken into account. 
Multi drug resistant (MDR) TB cases were not 
considered in this study. In these TB subjects, the anti 
TB drug (A-TB) therapy was started within 0-15 days. 
 
N.B (Nota bene)  
In this study, all the subjects (groups-1, 2 and 3) 
having normal liver and kidney function, normal 
serum glucose level (that is not suffering from 
diabetes mellitus) were considered. 
 
Collection of blood 
About 2 mL of blood was collected from each 
subject by venipuncture and the blood was left to clot; 
the serum so obtained was stored in the refrigerator at 
2-4C until assayed. It is to mention that the assay for 
GS in serum was done on the same day after 
preparation of the serum. Serum was also collected in 
the same procedure after exactly thirty (30) days in 
tubercular subjects with usual treatment (A-TB drugs). 
The tubercular subjects were under Directly Observed 
Treatment (DOT) programme under Revised National 
Tuberculosis Control Programme (RNTCP). 
 
Methods 
 
Assay of serum GS 
The highly specific method of transfer reaction was used 
for measuring GS activity
12
. The glutamyl hydroxamate 
so formed by the reaction; L-glutamine+Hydroxylamine
 glutamyl hydroxamate+NH3; in presence of 
sodium arsenate and ADP; is made to react with ferric 
chloride (Fecl3) to form orange brown coloured  
-glutamyl hydoxamate-Fe+3 complex. The OD of the 
product was measured at 540 nm. The GS activity in milli 
Units (mu)/mL was determined from a standard curve 
drawn with a pure sample of -glutamyl-hydroxamate. 
One unit of enzyme is equivalent to the amount of 
glutamine synthetase that can produce one micro-mole of 
-glutamyl-hydroxamate per minute at 37C. 
The capacity of L-methionine-S, R sulfoximine 
(MSO) to inhibit GS activity was determined. MSO is 
a well defined GS inhibitor having greater specificity 
for M. tuberculosis GS than for mammalian GS
8
. 
MSO is very much soluble in water or transfer 
reaction. 
Initially, the serum collected at first time from 
tubercular subject was added to the transfer reaction 
in definite proportion which did not contain  
L-glutamine, the substrate, (hence it might be called 
modified transfer reaction ingredients) and then to this 
was added MSO at a concentration of 5, 50 and  
500 µM, respectively. The mixture was incubated at 
37C for two hours. The incubated mixture was then 
added separately to a standard transfer reaction 
mixture and incubated at 37C. It was then subjected 
for the usual procedure for measuring the 
concentration of -glutamyl hydroxamate. The result 
so obtained was expressed as a percentage of the 
initial serum GS activity in tubercular subjects that is 
without any incubation of serum with MSO. This part 
of the study was exclusively meant only to determine 
the percentage of activity reduction of GS in serum of 
tubercular subjects when incubated with different 
concentrations of MSO. The level of serum GS as 
obtained on first time for the tubercular subject was 
taken as 100% for the individual. Then after the 
incubation of the said serum with different 
concentrations of MSO (5, 50 and 500 µM, 
respectively) the serum GS was assayed. The activity 
of serum GS so obtained after incubating serum with 
MSO was expressed individually as a percentage of 
initial level taking the initial level (that is without any 
incubation with MSO) of serum GS activity as 100%. 
For example, let the initial level of serum GS of a 
tubercular subject be 10 mu/mL and the serum GS 
activity after the said incubation with MSO for the 
same individual be 2 mu/mL. Then, taking the initial 
value (that is 10 mu/mL) as 100%, the percentage 
activity of serum GS becomes 20% after incubation. 
The percentage activity so obtained individually was 
computed collectively for tubercular subjects and 
expressed as Mean value ± Standard deviation. 
In the similar fashion, purified human liver GS was 
also assayed after incubating it with MSO of similar 
concentration as done with serum. The result was 
expressed as percentage of initial value of purified 
human liver GS, taking the supplied standard purified 
human liver GS concentration value as 100%. 
 
Results 
All the patients with active tuberculosis, whether 
pulmonary or extra pulmonary and A-TB drugs 
started between 0-15 days; had detectable GS activity 
in their sera; whereas none of the normal control 
subjects or lung disease control subjects (not suffering 
from TB) had detectable GS in their sera (Tables 1 & 2). 
In all the patients with tuberculosis, both pulmonary 
and extra-pulmonary, the serum GS activity declined 
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significantly with anti TB drugs, as reflected by the 
lower values of GS activity in the second sample of 
patient’s ‘sera obtained after additional thirty days’ 
treatment with anti TB drugs. The serum GS activity 
reduced to a considerable extent when the serum of 
tubercular subjects was incubated with MSO. At a 
dose of 5, 50, 500 µM of MSO, the serum GS 
activities were reduced to 20.2±2.4%, 14.4±1.3% and 
4.3±0.7%, respectively, of the initial activity (the 
initial activity was taken as 100%) (Table 3). 
Therefore, while increasing the dose of MSO the 
degree of mycobacterial GS activity reduction was 
increased. However, the purified human liver GS, 
when incubated with the similar doses of MSO as 
control, showed activity of 84%, 73% and 57%, 
respectively, (the initial activity was taken to be 
100%) (Table 3). 
 
It is calculated that with further treatment (with  
A-TB drugs) for another one month, there is a fall of 
Table 2 — Serum GS activity in pulmonary tubercular subjects (Group 3A) 
Sr. No. Age 
(years) 
Sex Sputum positivity for TB bacilli Serum GS level in mu/mL 
At 0-15 days of treatment  
with A-TB drugs 
Additional treatment for  
1 month with A-TB drugs 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
36 
45 
24 
42 
32 
18 
28 
47 
28 
37 
35 
30 
41 
35 
33 
F 
F 
M 
M 
M 
M 
F 
M 
F 
F 
M 
M 
M 
M 
F 
No 
Yes 
Yes 
Yes 
No 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
7.67 
10.60 
16.87 
17.23 
6.82 
12.84 
15.68 
17.12 
15.62 
14.84 
11.46 
17.80 
12.40 
11.46 
16.85 
2.13 
3.14 
2.67 
2.73 
2.58 
3.69 
3.60 
2.94 
2.84 
3.12 
2.86 
2.47 
3.08 
2.63 
3.14 
Serum GS activity in extra pulmonary tubercular subjects (Group 3B) 
Sr. No. Age (yrs) Sex Diagnosis Serum GS level in mu/mL 
At 0-15 days of treatment  
with A-TB drugs 
Additional treatment for  
1 month with A-TB drugs 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
40 
18 
49 
9 
53 
62 
14 
42 
8 
54 
11 
37 
34 
22 
10 
F 
M 
M 
F 
M 
M 
F 
M 
F 
M 
M 
F 
M 
F 
M 
Both sided tubercular pleural effusion 
TB lymphadenitis 
Spinal TB 
TB lymph gland 
Intestinal TB 
Rt sided tubercular pleural effusion 
TB lymph gland 
TB hip jt. 
TB meningitis 
Lupus vulgaris 
Miliary TB 
Rt sided TB pleural effusion 
Urinary bladder TB 
Rt sided TB pleural effusion 
TB meningitis 
10.04 
7.96 
15.35 
16.32 
11.46 
14.32 
13.83 
16.48 
14.87 
10.22 
13.37 
6.72 
11.80 
12.90 
15.75 
2.27 
2.94 
4.07 
5.82 
2.84 
3.14 
2.72 
3.86 
3.37 
2.78 
4.80 
2.08 
3.14 
4.83 
4.92 
Table 1 — Serum GS activity in normal control subjects  
(Group-1) 
No. of subjects Age range of the subjects 
(years) 
Level of GS in the 
serum (mu/mL) 
23 12 – 48 Not detectable at all  
in all the subjects 
Serum GS activity in lung disease control subjects (Group-2) 
26 14 – 52 Not detectable at all  
in all the subjects 
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serum GS activity by an average of 74.1±3.8% in 
patients with pulmonary TB and 72.8±2.8% in 
patients with extra-pulmonary tubercular subjects. It 
is also noteworthy that almost similar observation had 
been noticed in both pulmonary and extra-pulmonary 
tubercular subjects. 
 
Discussion 
As reported earlier, the decrease in serum GS 
activity in tubercular subjects was exaggerated more 
significantly with oral zinc supplementation  
(50 milligrams of elemental zinc daily) for one month 
along with A-TB drugs
13
.Oral supplementation of 
zinc along with A-TB drugs in tubercular subject 
destabilizes the decompartmentalisation of iron and 
hastens the process of compartmentalisation of iron. 
Thus, it helps to prevent M. tuberculosis from getting 
iron
14
, which is very much needed as cofactor for the 
iron-cofactored superoxide dismutase (SOD) secreted 
extra-cellularly by the pathogenic mycobacteria to get 
the soluble oxygen by dismutation reaction which is 
very much needed for this obligate aerobe
15
. 
As also reported earlier, glutamine synthetase is  
an essential enzyme for the survival and growth of  
M. tuberculosis
5
.
 
The GS enzyme which lacks a  
leader sequence and is located in the bacterial 
cytoplasm, is released by the organisms growing  
in the medium(broth) as well as while growing  
within phagosomes in human mononuclear 
phagocytes. The abundant release of GS can be 
correlated with the prevalence of considerable amount 
of poly-L-glutamine/glutamate in the cell wall of 
these organisms
16
. 
In an earlier report, the average concentration of 
GS in normal control serum sample (n=35) was 
36±27 pg/mL and in the serum of healthy blood 
donors (n=24), it was 50±19 pg/mL. In that study, 
sandwich enzyme immunoassay and immunoblotting 
were applied to assay GS in serum. In the same study, 
the serum GS level was reported in patients with 
amyotrophic lateral sclerosis (n=8) as 116±6.2 pg/mL; 
with Alzheimer’s disease (n=9) as 111±53 pg/mL; 
with vascular dementia (n=15) as 72±59 pg/mL; with 
Parkinson disease (n=5) as 77±32 pg/mL and with 
schizophrenia (n=4) as 74±32 pg/mL. 
 
These values are very low when compared with the 
serum GS level in tubercular subjects and even 
undetectable by transfer reaction, the assay procedure 
applied in the present study. Therefore, the very little 
increase in the endogenous GS in serum with the said 
ailments will not interfere at all with this diagnostic 
for tuberculosis. So, the detection of serum GS by 
transfer reaction might be a useful parameter in the 
early and positive diagnosis of tuberculosis
17
. 
 
The specificity in the assaying procedure for GS 
activity was cent percent. The normal control subjects 
as well as lung disease control subjects had 
undetectable level of serum GS activity. However, the 
accuracy for assaying the mycobacterial GS activity 
can be increased by incubating the subject serum with 
MSO, a selective inhibitor of mycobacterial GS rather 
than human (mammalian) GS activity. 
 
So, the assay for serum level of GS will provide a 
faithful diagnosis for active tuberculosis. A gradual 
decrease in the serum level of mycobacterial GS (during 
the course of treatment with A-TB drugs) will indicate 
drug sensitivity. The assay is also helpful for detecting 
the reactivation of tuberculosis in latently infected 
subjects. Failure of serum GS level to come down from 
the very beginning would indicate primary drug 
resistance whereas a rebound in serum GS level after the 
fall primarily would indicate secondary drug resistance. 
 
In the present scenario, to have a substantial impact 
on the TB pandemic, a simple and rapid method for 
mycobacterial GS assay in the serum of suspected 
subjects might be instituted for field health workers. 
This will facilitate the early diagnosis and 
differentiation of the patients with TB from other 
patients having similar symptoms but suffering from 
other lung ailments. This would reduce the 
transmission of the disease substantially. 
 
The rapid serological test for the qualitative and 
quantitative analysis for serum GS might be done by 
using ELISA or latex agglutination. The wells might 
be coated with monoclonal or polyclonal antibodies 
specific to M. tuberculosis GS. Now, a measured 
amount of serum (with or without mycobacterial GS) 
Table 3 — Percentage of GS activity when incubated with MSO 
Concentration 
of MSO 
GS activity (percentage of initial level) 
Serum of pulmonary and  
extra pulmonary tubercular 
subjects (treatment started 
between 0-15 days) 
Total no. of subjects 
pulmonary TB-15 extra 
pulmonary TB-15 
Purified human 
liver GS 
NIL 100%  100% 
5 µM 20.2±2.4% 84% 
50 µM 14.4±1.3% 73% 
500 µM 4.3±0.7% 57% 
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might be added to the well and incubated at 37°C. To 
this, might be added a mixture containing glutamine, 
sodium arsenate, manganese chloride, hydroxylamine 
hydrochloride (neutralized with NaOH), ADP, tris 
hydrochloric acid in definite proportion and 
concentration. Now, after the proper incubation, the 
reaction might be stopped by the addition of definite 
volume of mixed reagent containing equal volumes of 
24% trichloroacetic acid, 6(N) HCl and 10% FeCl3 in 
0.02(N) HCl. If GS is present in the serum, an orange 
brown coloured -glutamyl hydroxamate-Fe+3 complex 
is formed, whose absorbance is measured at 540 nm 
spectrophotometrically. A standard curve is to be 
prepared with a pure sample of -glutamyl hydroxamate 
to determine the serum GS level in test serum in mu/mL. 
The specificity of the test might be increased with the 
use of MSO, a selective inhibitor of mycobacterial GS. 
By this technique, not only the definite diagnosis of 
active tuberculosis (both pulmonary and extra 
pulmonary) might be done; but also diagnosis of latent 
tubercular cases might be made. It also might enable us 
to know the success of the course of anti-tubercular 
drugs, or the development of primary or secondary drug 
resistant cases as mentioned earlier. 
For rapid field study to know the prevalence rate of 
tuberculosis at a particular region, a card impregnated 
with GS active substrate and reagent when kept in 
contact with a drop of test serum; the presence of  
M. tuberculosis GS would be evidenced by a visible 
colour change (orange brown) of the substrate. 
Therefore, with this assay there will be quick 
identification and rapid treatment of TB patients,  
which will result in the reduction of transmission of TB 
below the threshold needed to maintain the pandemic. 
Thus, the transmission of TB would eventually cease in 
theory.  
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